相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brief Report: Weight Gain Following ART Initiation in ART-Naive People Living With HIV in the Current Treatment Era
Stephanie A. Ruderman et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2021)
Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan
Naoki Kanda et al.
HIV MEDICINE (2021)
Weight gain before and after switch from TDF to TAF in a US cohort study
Patrick W. G. Mallon et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2021)
Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naive and Switch Scenarios in HIV-Infected Patients
Maria Saumoy et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Prevalence of obesity and disturbances in glucose homeostasis in HIV-infected subjects and general population - missed diagnoses of diabetes?
A. Hanttu et al.
HIV MEDICINE (2021)
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E. Sax et al.
CLINICAL INFECTIOUS DISEASES (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
Nicola Squillace et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017
Mario Gomez et al.
INFECTION (2019)
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
Samir K. Gupta et al.
AIDS (2019)
Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back
Ana Milinkovic et al.
AIDS (2019)
Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting
Kai Juhani Kauppinen et al.
AIDS PATIENT CARE AND STDS (2019)
Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
Jason J. Schafer et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Joseph J. Eron et al.
AIDS (2018)
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
David Glidden et al.
CLINICAL INFECTIOUS DISEASES (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada
John R. Koethe et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2016)
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
Adrian S. Ray et al.
ANTIVIRAL RESEARCH (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
Jose R. Santos et al.
CLINICAL INFECTIOUS DISEASES (2015)
Intra-individual changes in body weight in population-based cohorts during four decades: the Finnish FINRISK study
Pia Pajunen et al.
EUROPEAN JOURNAL OF PUBLIC HEALTH (2012)
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Steven E. Kahn et al.
NATURE (2006)
分享论文
